Drug Trial Radar · NCT00023452
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,053
Actual
Start
Jun 2001
Primary completion
Oct 2010
Study completion Sep 2013
Sponsor
- Lead sponsor
- Centers for Disease Control and PreventionFederal agency
- Sponsor type
- Federal agency
- Collaborators
- US Department of Veterans Affairs
- First posted
- Sep 10, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent TB infection (LTBI).
Conditions
- Tuberculosis
Interventions
RPT + INH once weekly for 3 months given by DOTDrug
Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg. PLUS Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old. Therapy will be given by Directly Observed Therapy (DOT).
Isoniazid (INH) daily for 9 monthsDrug
Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants Less Than [<]18 Years of Age at 33 Months After EnrollmentTime frame: Baseline up to Month 33
Locations
26 sites in 4 countries. Site status is shown where the registry gives one.
Central Arkansas Veterans Health System
Little Rock, Arkansas
LA County/USC Medical Center
Los Angeles, California
UCSD Medical Center
San Diego, California
University of California, San Francisco
San Francisco, California
Denver Department of Public Health and Hospitals
Denver, Colorado
Washington, D.C. VAMC
Washington D.C., District of Columbia
Emory University, Department of Medicine
Atlanta, Georgia
Chicago VA Medical Center (Lakeside)
Chicago, Illinois
Hines VA Medical Center
Hines, Illinois
Johns Hopkins University School of Medicine
Baltimore, Maryland
Boston Medical Center
Boston, Massachusetts
New Jersey Medical School
Newark, New Jersey
Columbia University/Presbyterian Medical Center
New York, New York
Harlem Hospital Center
New York, New York
Carolinas Medical Center
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
University of North Texas Health Science Center
Fort Worth, Texas
Michael Debakey Veterans Affairs Medical Center
Houston, Texas
Audi L. Murphy VA Hospital
San Antonio, Texas
Seattle King County Health Department
Seattle, Washington
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil
University of British Columbia
Vancouver, British Columbia, Canada
University of Manitoba
Winnipeg, Manitoba, Canada
Montreal Chest Institute McGill University
Montreal, Quebec, Canada
Agencia de Salut Publica
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.